Vascular Endothelial Growth Factor (VEGF) Inhibitor Prevalent and Incident Use

Project Title Vascular Endothelial Growth Factor (VEGF) Inhibitor Prevalent and Incident Use
Date Posted
Thursday, May 9, 2013
Project ID

Modular program-based one-time assessment of the use of four different vascular endothelial growth factor (VEGF) inhibitors by generic drug name (bevacizumab, sorafenib, sunitinib, and thalidomide) in the Mini-Sentinel Distributed Database. A total of 3 different categories of counts were generated: (1) incident counts with respect to any of the four VEGF Inhibitors, (2) incident counts with respect to only the drug itself, and (3) prevalent counts (i.e., counts of users with at least one dispensing during the period of interest [2007-2010]). Modular programs are adaptable standardized programs. Results were generated using Modular Program 1; click here for more information. Programs were executed in August 2011.

If you are using a web page screen reader and are unable to access this document, please contact the Mini-Sentinel Operations Center for assistance by clicking on the Submit Comments link above or sending an email requesting assistance to

The information contained on this website is provided as part of FDA's commitment to place knowledge acquired from the Mini-Sentinel pilot in the public domain as soon as possible. Please read the disclaimer.

Medical Product
vascular endothelial growth factor (VEGF) inhibitor
Population / Cohort
All individuals
Time Period
2007 - 2010
Assessment Type
Exploratory Analyses
Study Type
Modular Program
Data Sources
Mini-Sentinel Distributed Database (MSDD)
FDA Center
Scroll to Top